PNPLA3 and hepatocellular carcinoma: Similar to the Ahmed et al. study, concordant variants had large effects on cardiometabolic disease and an increase in liver-related outcomes, while the discordant group (dominated by PNPLA3 and TM6SF2 variants) had larger effects on HCC and cirrhosis but no effect or even protection from CVD (105).